Transparency Life Sciences is a technology company.
Transparency Life Sciences has raised $5.0M across 1 funding round.
Transparency Life Sciences has raised $5.0M in total across 1 funding round.
Transparency Life Sciences has raised $5.0M in total across 1 funding round.
Transparency Life Sciences's investors include New Ventures Funds.
Transparency Life Sciences (TLS) is a biotechnology company pioneering open innovation in drug development, described as the world's first drug development company based on crowdsourcing and digital technologies.[1][2][4] It acquires promising new chemical entities and repurposed compounds to advance them through clinical trials, targeting significant unmet medical needs via patient-centric, all-digital protocols that leverage crowdsourcing, mobile health tech, and transparency to boost efficiency, data quality, and cost reduction.[1][2][3][7] TLS serves patients, physicians, researchers, and sponsors by solving core challenges in traditional clinical trials—such as high costs, patient burden, geographic limitations, and suboptimal protocols—through collaborative design and decentralized execution.[1][3]
Launched around 2012, TLS raised $5 million in Series A funding in 2018 from New Ventures III, signaling early growth momentum in digital clinical services amid regulatory tailwinds for tech-driven trials.[3][5] Its model transforms drug development by minimizing physical sites and emphasizing stakeholder input, positioning it as a disruptor in biopharma productivity.[1][3]
TLS was founded around 2012 by Tomasz Sablinski, M.D., Ph.D., as its inaugural CEO, drawing from his expertise alongside a team of executives from pharmaceutical, biotech, and high-tech sectors.[1] The idea emerged at a tipping point in biopharma, where productivity gains demanded radical innovation; Sablinski presented the vision at the 2012 Patient Centricity in Clinical Trials conference in Philadelphia, emphasizing crowdsourcing, telemedicine, and transparency for patient-centric trials.[1]
Key backers included industry veterans like David Nicholson, Ph.D., ex-Merck SVP, who endorsed TLS's breakthrough potential.[1] The company evolved from crowdsourced protocol design to a fully digital clinical services provider by 2018, securing $5 million Series A funding to scale its open innovation model.[3][5] Early traction built on assembling a world-class advisory board in crowdsourcing, tech, and media, humanizing its mission through stakeholder collaboration.[1]
TLS stands out in drug development through these key strengths:
These elements enable unprecedented productivity in advancing compounds from acquisition to trials.[1][3]
TLS rides the wave of digital transformation in clinical trials, fueled by rapid advances in mobile health, AI-driven crowdsourcing, and regulatory support for decentralized trials (e.g., FDA nods to remote tech post-2010s).[3] Timing aligns with biopharma's productivity crisis—stagnant R&D output despite rising costs—where traditional site-based models limit scale; TLS counters this with virtual, inclusive approaches amid post-pandemic acceleration of telehealth and patient-reported outcomes.[1][3]
Market forces like exploding health data volumes and stakeholder demands for transparency (e.g., AllTrials campaign alignment) favor TLS, influencing the ecosystem by democratizing trial design and inspiring hybrid models at big pharma.[2][4] It catalyzes broader adoption of open innovation, reducing barriers for smaller biotechs and improving trial success rates industry-wide.[1][6]
TLS is poised to expand as digital endpoints and real-world evidence become standard, potentially acquiring more assets for Phase II/III trials with AI-enhanced crowdsourcing. Trends like VR patient engagement, blockchain for data transparency, and global regulatory harmonization will amplify its edge, evolving it from pioneer to scale player—perhaps via partnerships with big pharma or fresh funding rounds. As the first mover in open digital drug dev, TLS could redefine productivity, delivering therapies faster for unmet needs and hooking back to its founding promise of collaborative breakthroughs.[1][3]
Transparency Life Sciences has raised $5.0M across 1 funding round. Most recently, it raised $5.0M Series A in February 2018.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2018 | $5.0M Series A | New Ventures Funds |